Ceva Santé Animale
2015 Revenue: $937 million (€857 million)
HQ: Libourne, France
Marc Prikazsky, CEO of France’s Ceva Santé Animale, has made no secret of the fact that he wants his company to break into the top 5 animal health leaders by 2020. If 2015 is any indication, the company is well on its way to reaching that goal. Ceva’s revenues grew 12% in 2015, thanks in part to strong demand for its poultry vaccines Vectormune ND and Transmune. The company invests 10% of its turnover into R&D. In 2014, it launched an $8 million expansion of its U.S. business and it’s investing €80 million in 2016 in France, the U.S., Hungary and other countries. Ceva has also been hot on the acquisition trail, picking up its French neighbor Biovac, a vaccine maker, as well as Polchem, an India-based company that will help Ceva gain ground in that country’s rapidly growing poultry and dairy industries.
Ceva makes strides toward animal health dominance with strong 2015 sales
Ceva builds on vaccine expertise with Biovac buy
Ceva vows an ‘extremely responsive’ approach to U.S. animal health market